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BACKGROUND: Recombinant tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces tumour-selective apoptosis in
various pre-clinical models by binding its specific receptors expressed on cancer cells. Mapatumumab is a fully human monoclonal
antibody that is agonistic to the TRAIL Receptor 1 (TRAIL-R1).
METHODS: This phase II multicentre study was designed to evaluate the efficacy and safety of mapatumumab in patients with colorectal
cancer (CRC) who had failed to respond to, were intolerant to, or not candidates for fluoropyrimidine, oxaliplatin, and irinotecan-
based regimens. All patients received two loading doses of mapatumumab (20mgkg
 1 every 14 days), followed by maintenance
therapy with 10mgkg
 1 infused every 14 days.
RESULTS: A total of 38 patients, who had progressive disease after a median of three earlier chemotherapy lines, were enrolled. No
response according to the Response Evaluation Criteria in Solid Tumors was observed. A total of 12 patients (32%) achieved stable
disease for a median of 2.6 months. The median progression-free survival was 1.2 months. The most common adverse events
reported, regardless of relationship, were fatigue, nausea, anorexia, and abdominal pain. Plasma mapatumumab concentrations were
within the range of exposures predicted by the results of phase I studies of mapatumumab.
CONCLUSION: No clinical activity of single-agent mapatumumab was observed in patients with advanced refractory CRC. However, on
the basis of its favourable safety profile and pre-clinical evidence of potential synergy in combination with agents commonly used in
the treatment of colorectal cancer, further evaluation of mapatumumab in combination with chemotherapy is warranted.
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Colorectal cancer is one of the leading causes of cancer morbidity
and mortality worldwide, with approximately one million new
cases (9.4% of all cancers) and 4500000 deaths observed in 2002
(Parkin et al, 2005). About 25% of all colorectal cancer patients
have metastatic disease at diagnosis, and although the overall
5-year survival rate for patients with colorectal cancer in North
America is 65%, the rate drops to p10% in patients with
metastatic disease (Goldberg, 2005).
Standard treatment for patients with metastatic colorectal
cancer usually consists of combination therapy of 5-fluorouracil
with oxaliplatin or irinotecan. Prospective studies have demon-
strated that, in patients with metastatic colorectal cancer, these
combinations improve response rates, and progression-free and
overall survival compared with treatment with 5-fluorouracil alone
(Meyerhardt and Mayer, 2005). The introduction of monoclonal
antibodies targeting the epidermal growth factor receptor or the
vascular endothelial growth factor has further improved the
outcome of metastatic colorectal cancer patients. Thus, cetuximab,
panitumumab, and bevacizumab, administered as a single agent or
in combination with chemotherapy, have significantly expanded
the armamentarium of treatment options (Chung and Saltz, 2005).
Nevertheless, the long-term prognosis of these patients remains
poor.
The efficacy of cytotoxic anticancer drugs relies on their
propensity to trigger cellular effector pathways, such as cell cycle
arrest or apoptotic cell death. Apoptosis is a particularly desirable
treatment outcome, as it eradicates cancer cells without causing
a major inflammatory response, which could provide unwanted
survival signals. However, many cancers develop functional defects
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sin the drug-induced apoptosis pathway, which may lead to
constitutive or acquired resistance. To this end, alternative
pathways, such as the one activated by death receptors including
Fas/Apo-1, or tumour necrosis factor-related apoptosis-inducing
ligand Receptor 1 (TRAIL-R1) and TRAIL Receptor 2 (TRAIL-R2),
are being explored for cancer treatment. The TRAIL-R1 and
TRAIL-R2 are expressed in a broad range of solid tumours,
including carcinomas of the colon, lung, pancreas, ovary, cervix,
uterus, breast, and stomach, as detected by immunohistochem-
istry. Pre-clinical studies have shown that TRAIL and agonistic
antibodies directed to TRAIL receptors can induce apoptosis in
cancer cell lines and inhibit tumour growth in xenograft models
(Pukac et al, 2005; Ashkenazi, 2008; Humphreys and Halpern,
2008; Johnstone et al, 2008).
Mapatumumab, a recombinant, fully human agonist IgG1
monoclonal antibody that binds with high affinity to TRAIL-R1,
shows cytotoxic activity in vitro, and inhibits the growth of human
tumour cell lines, including colorectal cancer cell lines, in xenograft
models in vivo. In two phase I single-agent trials, mapatumumab
administered at doses ranging from 0.01 to 20mgkg
 1 was well
tolerated in patients with advanced solid tumours (Tolcher et al,
2007; Hotte et al, 2008). Adverse events, such as fatigue, fever, and
myalgia, were generally mild to moderate in severity. The maxi-
mum tolerated dose was not identified at doses up to 20mgkg
 1
administered every 28 days. In terms of efficacy, stable disease (SD)
was observed in a number of heavily pre-treated patients at several
dose levels. Therefore, doses of 10–20mgkg
 1 were believed to be
safe and potentially effective for further evaluation.
This multicentre phase II study was undertaken to evaluate the
efficacy, safety, and tolerability of mapatumumab at a dose of
20mgkg
 1 administered every 14 days (cycles 1 and 2), followed
by 10mgkg
 1 every 14 days in patients with advanced colorectal
cancer who had failed to respond to, were intolerant to, or not
candidates for a fluoropyrimidine-, oxaliplatin-, and irinotecan-
based regimen.
PATIENTS AND METHODS
Study design
This was an open-label, multicentre, single-arm phase II trial
conducted in four centres. The primary efficacy end point of the
study was tumour response defined by the Response Evaluation
Criteria in Solid Tumors (RECIST, Version 1.0; The ´rasse et al,
2000). Secondary efficacy end points were time to response,
duration of response, and progression-free survival (PFS). Overall
survival was not an end point of the study. Time to response was
defined for responders as time from first treatment to first partial
response (PR) or complete response (CR), which was subsequently
confirmed. Duration of response was defined for responders as
time from first PR or CR (which was subsequently confirmed) to
disease progression. Progression-free survival was defined as time
from first treatment to disease progression or death. The following
parameters were also evaluated: frequency and severity of
treatment-related adverse events, laboratory parameters, vital
signs, plasma mapatumumab concentrations, and mapatumumab
immunogenicity. The study was conducted according to the
principles of good clinical practice, the ethical principles stated
in the Declaration of Helsinki, and the local legal and regulatory
requirements. The protocol was approved by the institutional
review board at each study site. All patients gave written informed
consent.
Patient selection
Patients with relapsed or refractory histologically or cyto-
logically confirmed locally advanced or metastatic colorectal
adenocarcinoma not amenable to intervention with curative intent
were eligible for the study. Patients had to have failed, be intolerant
to, or not be candidates for fluoropyrimidine, oxaliplatin,
and irinotecan-based regimens. Monoclonal antibody treatment
including investigational monoclonal antibodies was not allowed
within the last 3 (murine or chimeric) or 8 weeks (human or
humanised). Eligibility criteria also included age X18 years;
an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1; measurable disease; no major surgery, radiation,
chemotherapy, or investigational agent within 4 weeks; adequate
organ function (absolute neutrophil count X1.5 10
9l
 1; platelet
count X100 10
9l
 1; aspartate transaminase (AST) and alanine
transaminase p2.5-fold the upper limit of normal (ULN) and
pfive-fold of the ULN if liver metastases were present; total
bilirubin p1.5-fold of ULN; serum creatinine ptwo-fold of ULN).
Exclusion criteria included the central nervous system metastasis;
Xgrade 3 neuropathy; history of earlier cancers within the last
5 years, except for basal cell carcinoma of the skin and in situ
cancers of the cervix; known human immunodeficiency virus
infection; known chronic or acute viral hepatitis; pregnancy or
breast-feeding; or a coexisting medical problem of sufficient
severity to limit study compliance.
Treatment and dose modifications
Mapatumumab was provided as a sterile, single-use, lyophilised
product. On reconstitution with 5.0ml sterile water for injection,
each vial contained 20mgml
 1 mapatumumab. Once reconsti-
tuted, mapatumumab was stored at 2–81C and infused within 8h.
In cycles 1 and 2 (1 cycle¼treatment with mapatumumab on
day 1, followed by 14 days of follow-up), each patient received
20mgkg
 1 body weight of mapatumumab, administered as an
intravenous infusion over 2h on day 1. In cycle 3 and in subse-
quent cycles, patients were treated with 10mgkg
 1 mapatumumab
on day 1. For cycle 3 and for subsequent cycles, the total adminis-
tration time was reduced to 1h. The dose and schedule of
mapatumumab were selected on the basis of a goal to achieve
steady-state concentration of mapatumumab more rapidly than
with the previously tested schedules (e.g., 10mgkg
 1 every 2 or
3 weeks).
Toxicity was graded according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC; Version 3.0). Dose-modify-
ing toxicities (DMT) were defined as any of the following events
if considered related to mapatumumab: grade 3 haematological
toxicity lasting p2 weeks or any grade 4 haematological toxicity,
grade 3 or greater non-haematological adverse event except
nausea/vomiting, diarrhoea, or fatigue for which the following
criteria were applied: grade 3 or greater persistent nausea/vomiting
in patients who had received optimal medical intervention and/or
prophylaxis, grade 3 or greater diarrhoea in patients who received
prophylaxis and treatment with anti-diarrhoeal agents, grade 4
fatigue. Mapatumumab dosing was continued at a reduced dose
if the DMT recovered to baseline or pgrade 1 within 2 weeks
of the scheduled treatment. Following a DMT at 20 or 10mgkg
 1,
the mapatumumab dose in all subsequent cycles was reduced to
10 or 3mgkg
 1, respectively. Patients were removed from the
trial for the following reasons: disease progression continued
with unacceptable toxicities despite optimal treatment or dose
reduction, intercurrent illness at the investigator’s discretion,
withdrawal of consent, non-compliance, lost to follow-up, and
pregnancy.
Assessments
Clinical and laboratory assessments (complete blood count (CBC)
with differential, liver function test, urine analysis) were performed
every week. Disease assessments were obtained at baseline (within
4 weeks of study entry) and every 6 weeks, or at every three cycles
Phase II trial of mapatumumabin
T Trarbach et al
507
British Journal of Cancer (2010) 102(3), 506–512 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s(1 cycle¼treatment with mapatumumab on day 1, followed by
14 days of follow-up). Tumour response evaluation was based on the
RECIST criteria (Version 1.0; The ´rasse et al, 2000). Patients were
followed up for a minimum of 28d a y sa f t e rt h ef i n a ld o s eo f
mapatumumab.
Pharmacokinetic assessment – plasma pharmacokinetic
sampling and assay
Blood specimens were collected in EDTA-coated vacutainer tubes
before the administration of mapatumumab, and at the completion
of dosing in cycles 1, 2, 3, and 6; at the time of disease assessment
on or following the day 8 visit at cycles 3 and 6; and at a minimum
of 28 days after the final dose of mapatumumab. If a patient
received more than six cycles of mapatumumab therapy, a
specimen was collected at the time of disease assessment in every
third treatment cycle (i.e., cycles 9, 12, etc.). Blood samples were
centrifuged at 1.500g for 10min immediately after collection, and
plasma was stored frozen at  701C until assayed.
Determination of plasma mapatumumab concentrations
Plasma samples were analysed for mapatumumab by an enzyme-
linked immunosorbent assay (ELISA) using TRAIL-R1:FLAG
capture and horseradish peroxidase-labelled anti-human lambda
antibody detection. The signal was amplified by the addition of
tetramethylbenzidine, followed by absorbance measurement at
450nm. The assay had a lower limit of quantitation of 100ngml
 1
in undiluted serum.
Plasma mapatumumab concentration data are summarised
using mean, median, s.e.m., s.d., coefficient of variation (% CV),
geometric mean, 95% confidence interval, and number of patients.
Statistical analysis was performed and data appendices were
created using either WinNonlin Enterprise (Version 4.1; Pharsight
Corp., Mountain View, CA, USA), GraphPad Prism (Version 4.02;
GraphPad Software, Inc., La Jolla, CA, USA), or SAS software
(Version 8.2; Cary, NC, USA).
The pharmacokinetic (PK) results were inspected for possible
effects of age, body weight, gender, study site, and baseline ECOG
score. The study was not prospectively designed to assess these
factors as potential covariates. Their impact on the plasma
mapatumumab concentration results was assessed by comparison
of 95% confidence interval between subgroups at corresponding
times.
Pharmacodynamic assessments
Paraffin blocks and/or unstained slides from the original resection
or biopsy of the primary tumour and/or other previous biopsies
were collected. In addition, if possible, samples of tumour tissue
safely amenable to biopsy were obtained at baseline and at one
additional time point at least 7 days after receiving mapatumumab
in any cycle. The primary use of these samples was the evaluation
of TRAIL receptor expression.
Immunohistochemical staining methods and materials
The immunohistochemical staining method used followed the
standardised protocol supplied by DAKO (Glostrup, Denmark) for
the investigational-use-only pre-prototype test reagent specific for
TRAIL-R1 (Humphreys and Halpern, 2008). Briefly, slides with
tissue sections were deparaffinised and hydrated, followed by heat-
induced epitope retrieval. A rabbit polyclonal antibody specific for
the extracellular portion of human TRAIL-R1 was applied, and a
polyclonal rabbit serum Ig was used as negative staining control in
parallel. Primary antibody binding signals were amplified using the
Envisionþ visualisation system (DAKO), and were detected
by enzymatic conversion of a substrate chromogen (303-diamino-
benzidine). Cell lines positive or negative for the target antigen
were used as staining controls for each experiment.
Staining was captured using a scoring method developed by
DAKO in which distribution and intensity are scored resulting in
distinct staining indices (Median Membrane Staining Intensity
(M-MSI)) and (Median Cytoplasm Staining Intensity (M-CSI)) for
the membrane and cytoplasmic compartments, respectively. Each
specimen was scored by a single observer.
Sample size justification and statistical analysis
A sample size of 30 patients was sufficient to evaluate the response
rate of mapatumumab in this population of relapsed or refractory
colorectal cancer patients. If no responses are observed, the exact
binomial 95% upper confidence limit on the response rate is 9.5%,
indicating that such an outcome would provide 95% confidence
that the underlying response rate is below this nominal level of
activity. If responses are observed, then single-agent activity is
indicated and the underlying response rate can be estimated with
the precision of approximately ±13%.
Statistical analysis
Because this study contained no control group and no randomisa-
tion to treatment groups, an intention-to-treat analysis was
not performed. Instead, the set of patients receiving at least one
dose of mapatumumab was included in the as-treated analysis.
The primary end point was tumour response as defined by RECIST
(Version 1.0). For the purposes of establishing SD, at least 4 weeks
from the baseline, measurement had to elapse without PD in order
to assign a best response of SD. Progression-free survival, a
secondary end point, was defined as time from first treatment to
disease progression or death.
RESULTS
Patient population
A total of 38 patients were enrolled in this study. Patient
characteristics are listed in Table 1. Of the patients, 55% were
male and the median age was 63 years. In all, 55% of patients
(21 out of 38) had an ECOG performance status of 0 and 45%
Table 1 Patient characteristics
Number of patients (%) (n¼38)
Gender
Male 21 (55)
Female 17 (45)
Age (years)
Median 63
Range 39–84
ECOG performance status
0 21 (55)
1 17 (45)
Number of previous systemic regimens
Median 3
Range 1–6
1 previous regimen 4 (11)
2 previous regimens 14 (37)
3 previous regimens 15 (40)
4 previous regimens 3 (8)
5 previous regimens 1 (3)
6 previous regimens 1 (3)
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included in this study were heavily pre-treated. The median
number of earlier systemic regimens was 3; 53% (20 out of 38) of
patients had received at least three treatment regimens for
colorectal cancer previously. Among the five patients who had
received more than three regimens earlier, the additional regimens
were generally variations of earlier ones. It is noteworthy that nine
patients (24%) had previously received cetuximab. Eight patients
(21%) had also received radiotherapy earlier. The patients had
extensive disease. As reported in the list of target and non-target
lesions at baseline, 84% (32 out of 38) of patients had liver lesions,
66% (25 out of 38) had lung lesions, 26% (10 out of 38) had lymph
node involvement, 8% (3 out of 38) had spleen involvement, and
26% (10 out of 38) had other lesions.
Efficacy
A total of 147 cycles of mapatumumab were administered. The
median number of cycles administered was 3 (range 1–9). There
was one single dose reduction (from 20 to 10mgkg
 1 at cycle 2)
because of non-haematological toxicity and four dose delays due to
non-haematological toxicity and administrative reasons. None of
the patients developed an objective tumour response as defined by
RECIST (Version 1.0; Table 2). A best response of SD maintained
for at least 4 weeks after the baseline assessment was observed for
12 patients (32%), with a median duration of 2.6 months. Modest,
short-lived tumour shrinkage of o10% was observed in one
patient. In the analysis of PFS, 24 disease progression events were
observed (63%), including two deaths due to malignant disease.
For all 38 patients, the median PFS was 1.2 months, with a range of
0.0–4.0 months. In 6 of the 38 patients (16%), a PFS of X8 weeks
was observed.
Safety
A summary of treatment-emergent adverse events, regardless of
the relationship to mapatumumab, which occurred in 410% of the
38 patients, is shown in Table 3. The most common adverse events
were fatigue (37%), nausea (29%), anorexia (24%), and abdominal
pain (21%). Most of these events were mild to moderate in severity.
The adverse events considered at least possibly related to
mapatumumab, which were observed in 45% of patients,
comprised diarrhoea (8%), vomiting (8%), and pyrexia (8%).
The majority of the related adverse events were mild to moderate
in severity.
A total of 11 patients experienced a serious adverse event
resulting in hospitalisation. The serious adverse events were
considered not to be mapatumumab related by the investi-
gators, with the exception of one event of vomiting. Overall,
the most common serious adverse events were ascites, ileus,
nausea, fatigue, anorexia, and renal failure, each occurring in
two patients.
Summaries of the highest NCI-CTC toxicity grades for selected
haematology parameters are presented in Table 4. Leukocytes,
neutrophils, and platelets remained within normal limits in 484%
of patients while receiving mapatumumab. Among the 38 patients,
grade 1 and grade 2 neutropaenia were reported in 4 (11%) and
1 (3%) patients, respectively. Grade 2 (12 out of 38, 32%), grade 3
(3 out of 38, 8%), and grade 4 (1 out of 38, 3%) lymphocytopaenia
were observed in 16 out of 38 patients. A total of 6 patients (16%)
developed shifts of at least 2 grades from baseline for lymphocytes.
There were no significant clinical sequelae reported from these
changes in lymphocyte counts. Out of the 38 patients, grade 2
thrombocytopaenia was reported in 2 (5%) patients, grade 1
anaemia was observed in 16 (42%) patients, grade 2 in 10 (26%)
patients, and grade 3 in 1 (3%) patient.
No significant haepatotoxicity or renal toxicity was observed.
However, at baseline, 22 out of 38 (55%) patients had grade 1 or 2
elevations of AST. Shifts of X2 grades from baseline in AST and/or
alanine transaminase were observed in 4 out of 38 (11%) patients.
Five patients had grade 3 or 4 alanine transaminase, AST, and/or
total bilirubin levels (Table 4). All five of these patients had known
liver metastases at study entry and died of progressive disease or
its complications.
A total of 152 samples from 38 patients were assayed for
immunogenicity to mapatumumab during this study. No anti-
mapatumumab antibodies were detected.
Table 2 Summary of best response
Number of patients (%) (n¼38)
Evaluable 35 (92)
CR —
PR —
SD 12 (32)
95% CI 18–49
Median duration of SD (months) 2.6
95% CI 2.6–2.8
PD 23 (61)
95% CI 43–76
Not evaluable 3 (8)
Early death
a 1 (3)
Insufficient data 2 (5)
Abbreviations: CI¼confidence interval; CR¼complete response; PD¼progressive
disease; PR¼partial response; SD¼stable disease.
aDeath due to progressive disease.
Table 3 Summary of the most frequent treatment-emergent
a adverse
events (n¼38)
All grades,
n (%)
Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%) Grade 4
Fatigue 14 (37) 8 (21) 9 (11) 2 (5) —
Nausea 11 (29) 3 (8) 4 (11) 4 (11) —
Anorexia 9 (24) 5 (13) 3 (8) 1 (3) —
Abdominal pain 8 (21) 3 (8) 1 (3) 4 (11) —
Diarrhoea 6 (16) 3 (8) 3 (8) — —
Dyspnea 6 (16) 1 (3) 1 (3) 4 (11) —
Peripheral oedema 6 (16) 3 (8) 2 (5) 1 (3) —
Vomiting 6 (16) 2 (5) 1 (3) 3 (8) —
Insomnia 5 (13) 3 (8) 2 (5) — —
Pyrexia 5 (13) 3 (8) 2 (5) — —
Ascites 4 (11) 1 (3) 1 (3) 2 (5) —
Back pain 4 (11) 2 (5) 2 (5) — —
Constipation 4 (11) 2 (5) 1 (3) 1 (3) —
Cough 4 (11) 1 (3) 3 (8) — —
aRegardless of study drug relationship.
Table 4 Selected haematologic, hepatic and renal toxicities (according
to NCI-CTC criteria) in all mapatumumab-treated patients (n¼38)
Grade 0,
n (%)
Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%)
Grade 4,
n (%)
Leukocytes 32 (84) 5 (13) 1 (3) — —
Neutrophils (ANC) 33 (87) 4 (11) 1 (3) — —
Lymphocytes 22 (58) — 12 (32) 3 (8) 1 (3)
Platelets 36 (95) — 2 (5) — —
Haemoglobin 11 (29) 16 (42) 10 (26) 1 (3) —
AST 12 (32) 13 (34) 8 (21) 4 (11) 1 (3)
ALT 21 (55) 11 (29) 5 (13) — —
Total bilirubin 29 (77) 3 (8) 5 (13) — 1 (3)
Creatinine 24 (63) 8 (21) 5 (13) — 1 (3)
Abbreviations: ANC¼absolute neutrophil count; ALT¼alanine transaminase;
AST¼aspartate transaminase.
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sPharmacokinetics
All patients had measurable plasma mapatumumab concentrations
after dosing (Figure 1). The plasma mapatumumab concentrations
observed in this study were generally within the range of expected
concentrations predicted from PK results in previous phase I
studies (Tolcher et al, 2007; Hotte et al, 2008). Gender, age, weight,
study site, and baseline ECOG performance status had no apparent
effect on mapatumumab exposure. There were no apparent
differences in plasma mapatumumab concentrations for patients
with stable vs progressive disease, or in patients who experienced
serious adverse events and those who did not.
Immunohistochemistry
Paraffin-embedded tissue blocks or 5–10 slides, each with a
replicate 3–5mm tumour tissue section, were provided for 32 of
the 38 study patients (84%). A single tissue specimen was provided
for 27 patients, and multiple specimens (2–3, collected from
different anatomic sites or at different times) were provided for
five patients. Most specimens were archival, and were collected
8–64 months before enrolment; one biopsy specimen was collected
from a patient on the day of the first mapatumumab adminis-
tration. All 36 specimens collected were considered to be evaluable
after staining. Supplementary Table 1 provides a listing of
membrane and cytoplasmic staining results for each patient. The
staining index for each compartment covers a possible range of
0–300, with strong staining weighted more heavily than weak
staining. As previously observed, staining was variable within and
between tumour specimens (Humphreys and Halpern, 2008). Most
specimens (28 of 36, 78%) had specific TRAIL-R1 staining on at
least 20% of tumour cells. Of these, 20 specimens (20 of 28, 71%)
had staining of at least 50% of tumour cells, with staining
predominantly cytoplasmic for all but 2 of these 20 specimens (18
of 28, 64%). Three patients did not show detectable staining for
TRAIL-R1 in any specimen, and one other patient had a negative
specimen and two specimens with weak staining that had been
collected at a later date. Most specimens had a mixture of cyto-
plasmic and membrane staining. However, weak or no membrane
staining with stronger cytoplasmic staining was identified for 11
specimens (11 of 28, 39%) from 10 patients, and there was also one
example of stronger membrane staining.
Three patients provided specimens collected at different times
during their disease course; of these, one set of specimens was
consistently negative, one set showed stronger staining earlier in
the disease course than at baseline, and one set was initially
negative, but demonstrated stronger staining in the specimen
collected more recently. In general, the intensity, distribution, and
heterogeneity of staining of these specimens were similar to that
observed in an independent panel of colorectal carcinoma
specimens evaluated using this method (Humphreys and
Halpern, 2008).
DISCUSSION
The primary objective of this phase II clinical study was to assess
the tumour response to mapatumumab administered in two load-
ing doses of 20mgkg
 1 every 14 days (cycles 1 and 2), followed by
maintenance therapy with 10mgkg
 1 every 14 days, in patients
with refractory advanced colorectal cancer. None of the 38 treated
patients developed a response according to RECIST (Version 1.0).
Twelve patients had SD of a minimum duration of at least 4 weeks.
Modest, short-lived tumour shrinkage of o10% was observed in
one patient. The median PFS for the 38 study patients was 1.2
months. Hence, when administered as a single agent, mapatumu-
mab did not demonstrate the ability to shrink tumours or generate
a clinically meaningful response in this population of heavily pre-
treated refractory colorectal cancer patients. Similar results were
also reported with mapatumumab in patients with pre-treated
advanced non-small-cell lung cancer (Greco et al, 2008). However,
two complete and one partial responses were reported in patients
with relapsed or refractory follicular lymphoma receiving mapa-
tumumab (Younes et al, 2005), demonstrating that single-agent
mapatumumab has activity at these doses.
Resistance to TRAIL receptor (TRAIL-R)-mediated signalling in
colorectal cancer has been observed in both colorectal cell lines
and ex vivo transplants of patient tumours grown in mouse
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Figure 1 Individual plasma mapatumumab concentrations. Plasma mapatumumab concentrations observed for individual subjects after two 20mgkg
 1
mapatumumab intravenous infusion doses given 14 days apart, with 10mgkg
 1 mapatumumab intravenous infusion doses given every 14 days thereafter,
with the expected minimum to maximum concentration range based on phase 1 study results.
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sxenografts. Resistance can be mediated at the cell surface through
changes in receptor expression levels and intracellular proteins
that impinge on both the extrinsic and intrinsic apoptotic
pathway.
Several pieces of evidence support the observation that
resistance to TRAIL-R signalling increases as tumours progress
from benign to advanced, metastatic disease. High levels of TRAIL
decoy receptor expression are associated with poor prognosis and
resistance to 5-fluorouracil (Granci et al, 2008) or oxaliplatin
(Toscano et al, 2008) and to increased levels of anti-apoptotic
proteins survivin and XIAP in metastatic colorectal cell lines
(Huerta et al, 2007). The importance of TRAIL-R levels in
determining sensitivity or resistance is validated by changes in
the TRAIL-R expression in response to chemotherapy, radiation,
or steroids that are associated with increased responsiveness
(Gong et al, 2006; Kouhara et al, 2007; Oikonomou et al, 2007).
Overexpression of the anti-apoptotic protein, FLIP-L, has been
demonstrated to be a prognostic factor in colorectal cancer
(Heijink et al, 2007; Korkolopoulou et al, 2007; Ullenhag et al,
2007). Experimental manipulation of FLIP (Wilson et al, 2007) and
XIAP (Toscano et al, 2008; Connolly et al, 2009; Wilson et al, 2009)
has confirmed their critical role in mediating resistance against
TRAIL-R-dependent apoptosis. High levels of the anti-apoptotic
proteins Bcl-xL (Schulze-Bergkamen et al, 2008), BAG-1 (Clemo
et al, 2008), AKT, and Bax (Niyazi et al, 2009) also mediate TRAIL
resistance in colorectal cell lines.
In pre-clinical studies, mapatumumab activity is more impressive
when combined with chemotherapeutic agents (Pukac et al, 2005).
In colorectal cancer cell lines COLO205, HCT116, and SW480, the
combination of mapatumumab and 5-fluorouracil, topotecan, or
irinotecan demonstrated significantly higher cytotoxicity than either
chemotherapy or mapatumumab alone, suggesting a potential for
synergy. In an SW480 colorectal cancer xenograft model, adminis-
tration of mapatumumab, in combination with topotecan, resulted
in significant inhibition, compared with single-agent topotecan.
Similarly, enhanced cell killing was observed in NSCLC (H460),
breast (MDA-MB-231), lymphoma (ST486), and ovarian (SKOV3)
cancer models when mapatumumab was combined with different
chemotherapeutic agents (Pukac et al, 2005). Potential mechanisms
that could explain the pre-clinical synergy between mapatumumab
and chemotherapy include increased expression of death receptors,
increased expression of pro-apoptotic Bax/Bak family members, and
decreased expression of anti-apoptotic Bcl-2/Bcl-XL family mem-
bers and IAPs (Thorburn et al, 2008). Redistribution and clustering
of death receptors in cells treated with chemotherapeutic agents and
modulation of death-inducing receptor complex components have
also been reported (Elrod and Sun, 2008; Yu and Shi, 2008).
Hence, after this phase II monotherapy study, a logical step
would be to explore mapatumumab in combination with chemo-
therapy agents in patients with advanced colorectal cancer. In this
regard, other biological agents, notably bevacizumab, had limited
activity in colorectal cancer as a single agent but improved survival
when combined with standard chemotherapy regimens (Hurwitz
et al, 2004).
A secondary objective of this study was to evaluate the safety and
tolerability of mapatumumab in this heavily pre-treated patient
population. In general, mapatumumab was well tolerated. The
toxicity profile of mapatumumab observed in this study was
consistent with that in single-agent phase I studies (Tolcher et al,
2007; Hotte et al, 2008). Most adverse events reported to be
mapatumumab related were mild to moderate in severity.
Mapatumumab did not seem to markedly affect haematological
parameters other than lymphocyte counts. In this study, 42% of
patients experienced lymphopaenia, consistent with other pre-
viously published single-agent mapatumumab studies (Tolcher et al,
2007; Greco et al, 2008; Hotte et al, 2008). None of these transient
lymphocytopaenias were associated with clinically relevant infec-
tions, but subsequent studies of mapatumumab should evaluate this
further, for example, by characterising lymphocyte subsets in
patients who experience lymphocytopaenia, especially as TRAIL
targets certain lymphocyte subsets (Janssen et al, 2005).
Importantly, in this study, mapatumumab exhibited no relevant
haepatotoxicity, an a priori concern in the light of pre-clinical
studies of TRAIL receptor agonists (Yin and Ding, 2003; Mori et al,
2004; Zheng et al, 2004). The safety profile of single-agent
mapatumumab administered at doses of up to 20mgkg
 1 every
14 days in heavily pre-treated advanced colorectal cancer patients
was quite favourable.
The heterogeneity of immunohistochemistry staining for
TRAIL-R1 observed in this study was consistent with that of
earlier observations. The lack of responses to single-agent
mapatumumab precluded any evaluation of association between
receptor expression and clinical outcome.
Early safety results from ongoing clinical trials of mapatumu-
mab with several chemotherapy regimens are promising (Leong
et al, 2009; Mom et al, 2009). Results reported to date have shown
that the combinations tested (i.e., paclitaxel, carboplatin plus
mapatumumab, as well as gemcitabine, cisplatin plus mapatumu-
mab) were safe and well tolerated. On the basis of the results of the
current study, as well as on the pre-clinical evidence of synergy in
combination with commonly used agents in colorectal cancer, and
the encouraging safety and efficacy data reported in the ongoing
clinical trials of mapatumumab combined with full-dose chemo-
therapy, clinical trials of mapatumumab in combination with
standard chemotherapy agents in patients with advanced colo-
rectal cancer are warranted.
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